Mineralys director sells 3,000 shares at $28.58

Mineralys Therapeutics director Daphne Karydas exercised options and sold 3,000 shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) director Daphne Karydas reported an option exercise and share sale on September 15, 2026. She exercised stock options for 3,000 shares of common stock at an exercise price of $12.02 per share, leaving 35,000 options outstanding under that award. On the same date, she sold 3,000 common shares at $28.58 per share. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025, and the option is scheduled to vest in 36 monthly installments beginning October 13, 2023, with an expiration date of September 13, 2033.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,000 shares ($50K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Karydas Daphne

Role Director

Sold 3,000 shs ($86K)

Approx. gross sale proceeds $86K

Approx. exercise cost $36K

Approx. pre-tax spread $50K

Type	Security	Shares	Price	Value
Exercise	Stock Option F1, F2	3,000	$0.00	$0.00
Exercise	Common Stock F1	3,000	$12.02	$36K
Sale	Common Stock F1	3,000	$28.58	$86K

Holdings After Transaction: Stock Option — 35,000 contracts (Direct); Common Stock — 6,200 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.
2. F2. The stock option vests in 36 monthly installments beginning on October 13, 2023.

Key Figures

Shares sold: 3,000 shares Sale price per share: $28.58 per share Options exercised: 3,000 options +5 more

8 metrics

Shares sold 3,000 shares Common stock sale reported for September 15, 2026

Sale price per share $28.58 per share Price for 3,000 common shares sold on September 15, 2026

Options exercised 3,000 options Stock options converted into common shares on September 15, 2026

Option exercise price $12.02 per share Exercise price for 3,000 stock options

Remaining options 35,000 options Stock options remaining under the award after the exercise

Option expiration date September 13, 2033 Expiration date of the exercised stock option award

Rule 10b5-1 plan adoption date December 22, 2025 Date the trading plan governing these transactions was adopted

Option vesting schedule 36 monthly installments Vesting begins October 13, 2023 for the stock option

Key Terms

Rule 10b5-1 trading plan, stock option, vests in 36 monthly installments

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock option financial

"The stock option vests in 36 monthly installments beginning on October 13, 2023."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vests in 36 monthly installments financial

"The stock option vests in 36 monthly installments beginning on October 13, 2023."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MLYS director Daphne Karydas report on September 15, 2026?

She exercised stock options for 3,000 shares of Mineralys Therapeutics common stock at $12.02 per share and sold 3,000 shares of common stock at $28.58 per share on September 15, 2026.

Were the September 15, 2026 MLYS insider trades by Daphne Karydas under a Rule 10b5-1 plan?

Yes. The filing states the transactions “were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025,” indicating they were pre-arranged under that plan.

What options did Daphne Karydas exercise in the latest MLYS Form 4?

She exercised stock options covering 3,000 shares of Mineralys Therapeutics common stock at an exercise price of $12.02 per share. After this exercise, the reported balance under that option award is 35,000 options remaining.

At what price did MLYS director Daphne Karydas sell shares on September 15, 2026?

She sold 3,000 shares of Mineralys Therapeutics common stock at a price of $28.58 per share on September 15, 2026, according to the Form 4 disclosure.

How do the exercised options for MLYS vest and when do they expire?

The filing notes the stock option “vests in 36 monthly installments beginning on October 13, 2023” and carries an expiration date of September 13, 2033 for that option award.

How many Mineralys Therapeutics options does Daphne Karydas hold after the reported transactions?

After exercising 3,000 options, the Form 4 reports that 35,000 options remain outstanding for that stock option award held by director Daphne Karydas.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 05:41 PM Accepted by SEC EDGAR 09/17/2026 - 05:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Karydas Daphne

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M(1)		3,000	A	$12.02	9,200	D
Common Stock	09/15/2026		S(1)		3,000	D	$28.58	6,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$12.02	09/15/2026		M(1)			3,000	(2)	09/13/2033	Common Stock	3,000	$0	35,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

2. The stock option vests in 36 monthly installments beginning on October 13, 2023.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)